Specifically, there were no significant associations between low or high tumor HA scores according to pathologic grade (Fisher’s exact test, two-tailed p = 0.7105), gender (p = 1.0000), race (p = 0.7984), KRAS mutation status (p = 1.0000), EGFR mutation status (p = 0.7524), family history of cancer (p = 0.3989), Eastern Cooperative Oncology Group (ECOG) performance status (PS, p = 0.3288), HA biopsy site (p = 0.3952), and line of therapy at the time of biopsy (p = 0.6619). This evidence concerns the gene KRAS and cancer.